Compugen (CGEN) Receivables (2009 - 2024)
Compugen recorded quarterly Receivables of $61.0 million in Q4 2023, up 2950.0% quarter-over-quarter from $2.0 million in Q4 2020.
Compugen's Receivables history runs 3 years deep, the most recent figure standing at $61.0 million for Q4 2023.
- In Q4 2023, Receivables changed N/A year-over-year to $61.0 million; the TTM figure through Dec 2023 stood at $61.0 million (changed N/A YoY), while the FY2023 annual figure was $61.0 million, changed N/A from the prior year.
- Receivables came in at $61.0 million for Q4 2023 at Compugen, up from $2.0 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $61.0 million in Q4 2023 to a low of $2.0 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Compugen | 234.03 Mn | 142.28 Mn | 352,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.74 Mn |
| Jun 30, 2024 | 9.80 Mn |
| Dec 31, 2023 | 63.53 Mn |
| Dec 31, 2022 | 2.42 Mn |
| Sep 30, 2021 | 10.03 Mn |
| Dec 31, 2020 | 4.66 Mn |
| Jun 30, 2016 | 1.73 Mn |
| Dec 31, 2015 | 9.15 Mn |
| Dec 31, 2010 | 5.02 Mn |
| Sep 30, 2010 | 1.38 Mn |
| Jun 30, 2010 | 250,000.00 |
| Mar 31, 2010 | 777,000.00 |
| Dec 31, 2009 | 1.44 Mn |
| Sep 30, 2009 | 408,000.00 |
| Jun 30, 2009 | 741,000.00 |
| Mar 31, 2009 | 403,000.00 |